Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-04-09Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating efficacy and safety of MRG003 in EGFR-positive advanced non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment [Phase 2]
Phase 2 trial assessing INC280 in combination with gefitinib for EGFR-mutated, c-MET-amplified non-small cell lung cancer after progression …
-
CLINICAL_TRIALS trial_result · 2021-04-08Clinical Trial Update: Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating maintenance targeted therapy with or without stereotactic body radiation therapy in stage IV non-small cell lung ca…
-
CLINICAL_TRIALS trial_result · 2021-04-06Clinical Trial Update: Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma [Phase 2]
Phase 2 trial evaluating toripalimab with bevacizumab, nab-paclitaxel, and carboplatin for untreated metastatic pulmonary sarcomatoid carcin…
-
CLINICAL_TRIALS trial_result · 2021-04-06Clinical Trial Update: Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer [Phase 1, Phase 2]
Phase 1/2 study of sacituzumab govitecan-hziy (IMMU-132) in adults with epithelial cancers; trial completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-04-06Clinical Trial Update: Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC [Phase 1, Phase 2]
Phase 1/2 trial of mocetinostat with durvalumab in advanced solid tumors and NSCLC was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-04-02Clinical Trial Update: Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery [Phase 3]
Phase 3 trial evaluating perioperative bronchodilator use in COPD patients undergoing lung cancer surgery; status currently UNKNOWN.
-
CLINICAL_TRIALS trial_result · 2021-04-02Clinical Trial Update: Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI [Phase 2]
Phase 2 trial update investigating neurocognition in NSCLC patients treated with osimertinib or osimertinib plus whole-brain irradiation (WB…
-
CLINICAL_TRIALS trial_result · 2021-04-01Clinical Trial Update: A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC [Phase 3]
Phase 3 trial comparing lorlatinib versus crizotinib in first-line ALK-positive non-small cell lung cancer; results have been posted.
-
CLINICAL_TRIALS trial_result · 2021-04-01Clinical Trial Update: Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer [Phase 2]
Phase 2 study comparing EC145 alone, EC145 plus docetaxel, and docetaxel alone for second-line non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2021-04-01Clinical Trial Update: To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion [Phase 4]
Clinical trial update evaluating afatinib for NRG1 fusion–positive non-small cell lung cancer in a Phase 4 study.
-
CLINICAL_TRIALS trial_result · 2021-03-26Clinical Trial Update: A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing MB02 to Avastin in stage IIIB/IV non-squamous non-small cell lung cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-03-24Clinical Trial Update: MK-3475 in Melanoma and NSCLC Patients With Brain Metastases [Phase 2]
Phase 2 trial update for MK-3475 (pembrolizumab) in melanoma and non-small cell lung cancer patients with brain metastases has completed wit…
-
CLINICAL_TRIALS trial_result · 2021-03-24Clinical Trial Update: T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer [Phase 2]
Phase 2 trial update on T cell receptor immunotherapy targeting NY-ESO-1 in NY-ESO-1 expressing cancers; study is completed with results pos…
-
CLINICAL_TRIALS trial_result · 2021-03-22Clinical Trial Update: Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) [Phase 1]
Phase 1 study evaluating pembrolizumab monotherapy and combination therapy in advanced solid tumors and lung cancer; completed with results …
-
CLINICAL_TRIALS trial_result · 2021-03-22Clinical Trial Update: Adjuvant CCRT vs CT in Minimal N2 NSCLC [Phase 2]
Phase 2 trial comparing adjuvant concurrent chemoradiotherapy to chemotherapy in minimal N2 non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2021-03-19Clinical Trial Update: Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib [Phase 2]
Phase 2 trial evaluating afatinib (Gilotrif) in advanced non-small cell lung cancer patients who were pre-treated with erlotinib or gefitini…
-
CLINICAL_TRIALS trial_result · 2021-03-17Clinical Trial Update: S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer [Phase 2, Phase 3]
A phase 2/3 trial (S1403) evaluated afatinib with or without cetuximab for newly diagnosed stage IV or recurrent EGFR-mutant non-small cell …
-
CLINICAL_TRIALS trial_result · 2021-03-17Clinical Trial Update: Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC [Phase 3]
Phase 3 clinical trial update for paclitaxel micelles/injection with cisplatin as first-line therapy in advanced non-small cell lung cancer …
-
CLINICAL_TRIALS trial_result · 2021-03-15Clinical Trial Update: A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC [Phase 3]
Phase 3 study of SHR-1210 with carboplatin and paclitaxel in squamous non-small cell lung cancer is ongoing, with status not provided.
-
CLINICAL_TRIALS trial_result · 2021-03-15Clinical Trial Update: Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC [Phase 3]
A Phase 3 trial evaluating anlotinib combined with icotinib as first-line therapy for patients with EGFR-mutant non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2021-03-15Clinical Trial Update: Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC [Phase 2]
Phase 2 trial assessing first-line therapy with Anlotinib plus Icotinib in EGFR mutation-positive non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2021-03-10Clinical Trial Update: Lorlatinib Combinations in Lung Cancer [Phase 1, Phase 2]
Phase 1/2 trial exploring lorlatinib combinations in lung cancer with ALK translocations and related resistant/metabolic alterations; status…
-
CLINICAL_TRIALS trial_result · 2021-03-09Clinical Trial Update: A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions [Phase 2]
Phase 2 trial update for lorlatinib in advanced ALK/ROS1-rearranged NSCLC with CNS metastasis and no measurable extracranial lesions.
-
CLINICAL_TRIALS trial_result · 2021-03-08Clinical Trial Update: Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR [Phase 2]
Phase 2 clinical trial update on almonertinib for advanced non-small cell lung cancer with rare EGFR mutations.